Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.

Dreucean, Diane; Nguyen, Steffany N; Donahue, Kevin R; Salazar, Eric; Ruegger, Melanie C

Dreucean, Diane; Nguyen, Steffany N; Donahue, Kevin R; Salazar, Eric; Ruegger, Melanie C.

Afiliación

Dreucean D; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA. ddreucean@houstonmethodist.org.
Nguyen SN; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.
Donahue KR; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.
Salazar E; Department of Pathology and Genomic Medicine - Houston Methodist Hospital, 6565 Fannin St, Houston, TX, 77030, USA.
Ruegger MC; Department of Pharmacy - Houston Methodist Hospital, 6565 Fannin St. DB1-09, Houston, TX, 77030, USA.

J Thromb Thrombolysis ; 52(1): 161-169, 2021 Jul.

Article en En | MEDLINE | ID: mdl-33099722

Asunto(s)

Inhibidores del Factor Xa/uso terapéutico; Pirazoles/uso terapéutico; Piridonas/uso terapéutico; Rivaroxabán; Tromboembolia Venosa; Anticoagulantes; Humanos; Piridonas/efectos adversos; Estudios Retrospectivos; Rivaroxabán/uso terapéutico; Tromboembolia Venosa/tratamiento farmacológico

Palabras clave

Anti-Xa; Apixaban; Direct oral anticoagulant; Rivaroxaban; Thrombosis; Treatment failure

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Piridonas / Tromboembolia Venosa / Inhibidores del Factor Xa / Rivaroxabán Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Thromb Thrombolysis Asunto de la revista: ANGIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google